Table 1. Baseline Clinical Characteristics.
| Characteristic | No. (%) |
|---|---|
| Clinical characteristic | |
| Male | 125 (62.5) |
| Female | 75 (37.5) |
| Age, mean (SD), y | 46.9 (14.0) |
| BSA, mean (SD), m2 | 1.8 (0.2) |
| Clinical symptoms | |
| Shortness of breath | 151 (75.5) |
| Chest pain or tightness | 195 (97.5) |
| Syncope or presyncope | 78 (39.0) |
| NYHA functional classification | |
| II | 58 (29.0) |
| III | 126 (63.0) |
| IV | 16 (8.0) |
| Family history of HCM | 67 (33.5) |
| Medications | |
| β-Blocker | 188 (94.0) |
| Calcium channel blocker | 23 (11.5) |
| History of other cardiac procedure | |
| Alcohol septal ablation | 5 (2.5) |
| ICD implantation | 2 (1.0) |
| Genetic characteristics | |
| No. (%) | 193 (96.5) |
| Pathogenic/likely pathogenic | 89 (46.1) |
| MYH7 | 57 (64.0) |
| MYBPC3 | 29 (32.6) |
| TNNI3 | 2 (2.2) |
| PTPN11 | 1 (1.1) |
Abbreviations: BSA, body surface area; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; MYBPC3, cardiac myosin-binding protein C variant; MYH7, beta-myosin heavy chain gene variant; NYHA, New York Heart Association; PTPN11, part of the RAS-MAPK signaling genes variant; TNNI3, cardiac troponin I variant.